LONDON--(BUSINESS WIRE)--The growing prevalence of various female health conditions has become a serious concern across the world. As a result, various female health initiatives are being carried out by several organizations, including non-government organizations (NGOs). These initiatives are aimed at enabling and encouraging female patients to discuss their problems with the concerned professionals and avail necessary treatment. Such initiatives targeted at early diagnosis of illnesses such as cervical cancer will lead to the growth of the market. Furthermore, this industry research report also presents a competitive analysis of the market by type (drugs and vaccines) and geography (Asia, Europe, North America, and ROW).
Competitive vendor landscape
The global cervical cancer therapeutics market is highly competitive with major vendors such as Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck & Co. Inc., and Novartis AG, competing based on price, quality, and market presence.
“The treatment currently available for cervical cancer includes chemotherapy and biologics, such as vaccines and monoclonal antibodies. However, there are only a few biologics that are approved for the treatment of cervical cancer, which offers a huge opportunity for the rise of other treatment options. T-cell-based immunotherapy is gaining significant traction and is expected to play a pivotal role in the diagnosis of cervical cancer. T-cell-based immunotherapy is more specific and is entitled with broader therapeutic potential for cervical cancer,” says a senior analyst at Technavio.
Top five cervical cancer therapeutics market vendors
Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co. is one of the leading global companies in the biopharmaceutical industry. The company is engaged in the discovery, development, licensing, manufacture, marketing, distribution, and sale of innovative medicines that help patients prevail over serious diseases. The company’s key offering for the treatment of cervical cancer includes TAXOL Injection, which is a clear, colorless to a slightly yellow viscous solution.
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. owns and operates businesses under two segments that include pharmaceuticals and diagnostics. The company offers AVASTIN (bevacizumab), which is a VEGF-directed recombinant humanized monoclonal IgG1 antibody.
GlaxoSmithKline Plc operates under three segments, namely pharmaceuticals, consumer healthcare, and vaccines. For the treatment of cervical cancer, the company offers CERVARIX, which is a vaccine used in females from 10 to 45 years of age to prevent early-stage cervical cancers (pre-cancerous lesions), pap smear abnormalities, and cervical cancer caused by HPV types 16 and 18.
Merck & Co., Inc.
Merck & Co. Inc. offers human health pharmaceutical and vaccine products, under its pharmaceutical segment. The company’s key offerings in the cervical cancer therapeutics market include GARDASIL, GARDASIL 9, and KEYTRUDA.
Novartis AG offers innovative medicines, under two business units, namely Novartis Pharmaceuticals and Novartis Oncology. The company offers HYCAMTIN, which is a topoisomerase inhibitor. HYCAMTIN (topotecan) for injection and intravenous use is supplied as a sterile, lyophilized, buffered, light yellow to greenish powder available in single-dose vials.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report, including the market size and forecast, drivers, challenges, trends, and more.
Browse Related Reports:
- Global Cancer Biologics Market 2019-2023 - The market research study identifies Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and Merck & Co., Inc as the leading players in the global cancer biologics market.
- Global Cervical Cancer Diagnostic Testing Market 2019-2023 - The market research study identifies Abbott Laboratories, BD, F. Hoffmann-La Roche, Hologic, and QIAGEN as the leading players in the global cervical cancer diagnostic testing market.
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at email@example.com.